These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 28948496)

  • 21. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
    Stein BL; Martin K
    Blood; 2019 Nov; 134(22):1902-1911. PubMed ID: 31778549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
    Stein BL; Martin K
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):397-406. PubMed ID: 31808903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pathogenesis of thrombosis in JAK2V617F myeloproliferative neoplasms].
    Guy A; James C
    Med Sci (Paris); 2019; 35(8-9):651-658. PubMed ID: 31532377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombotic incidents in patients with myelofibrosis suggest to be independent of
    Nikolova D; Radinov A
    Folia Med (Plovdiv); 2022 Aug; 64(4):655-660. PubMed ID: 36045460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Considerations and recommendations for a new molecular diagnostic algorithm for the myeloproliferative neoplasms.
    Haslam K; Langabeer SE
    Genet Test Mol Biomarkers; 2014 Nov; 18(11):749-53. PubMed ID: 25259626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
    Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
    J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
    Sun T; Zhang L
    Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Thrombosis in myeloproliferative neoplasms].
    Asakura H
    Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery.
    Andreescu M; Andreescu B
    Cureus; 2024 Mar; 16(3):e56008. PubMed ID: 38606222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
    Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
    BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms with Relation to Genetic Burden and Thrombosis.
    Ümit EG; Baysal M; Kırkızlar HO; Demir AM
    Turk J Haematol; 2024 Aug; 41(3):175-181. PubMed ID: 38801033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantification of JAK2V617F mutation load by droplet digital PCR can aid in diagnosis of myeloproliferative neoplasms.
    Zheng CF; Zhao XX; Chen XH; Liu Z; Wang WJ; Luo M; Ren Y; Wang HW
    Int J Lab Hematol; 2021 Aug; 43(4):645-650. PubMed ID: 33973741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
    Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
    Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Correlative study between JAK2 mutation and thrombosis in patients with myeloproliferative neoplasm].
    Xia L; Ding KY; Cai XY; Zhu WB; Liu X; Yang HZ; Wan X; Wu LL; Zeng QS; Wu JS
    Zhonghua Xue Ye Xue Za Zhi; 2010 Sep; 31(9):590-3. PubMed ID: 21122317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
    Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
    Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular characterization of chronic myeloproliferative neoplasias in México.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Ortiz-López R; Rivas-Llamas R; Gómez-Almaguer D; Ruiz-Delgado GJ
    Hematology; 2009 Oct; 14(5):261-5. PubMed ID: 19843380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of MPN beyond JAK2.
    Harrison CN; Garcia NC
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):348-54. PubMed ID: 25696878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.